INTERDISCIPLINARY COMMUNICATION BETWEEN UROLOGIST AND ONCOLOGIST AND ITS IMPLEMENTATION IN HORMONE REFRACTORY PROSTATE CANCER
Authors:
Marko Babjuk 1; Petr Brabec 2; Ladislav; Dušek 2; Tomáš Pavlík 2; Jindřich Fínek 3; Dalibor Pacík 4; Luboš Petruželka 5; Michaela Matoušková 6
Authors‘ workplace:
Urologická klinika 1. LF UK a VFN, Praha
1; IBA, Masarykova univerzita, Brno
2; Radioterapeutické a onkologické oddělení
FN, Plzeň
3; Urologická klinika, FN Bohunice, Masarykova
Univerzita, Brno
4; Onkologická klinika 1. LF UK a VFN, Praha
5; Urocentrum Praha
6
Published in:
Ces Urol 2009; 13(2): 149-160
Category:
Review article
Overview
Professional communication among physicians is currently of growing importance, namely in fields that stand in the centre of interest of two or more medical disciplines. It holds also for cancer diagnoses that are associated with urogenital system. Using advanced stages of prostate cancer as example, we introduce here technological and operational background of newly initiated project UJO („Urology Joins Oncology“). Th e project strives to facilitate collaboration between urologists and oncologists using modern ICTs. Non-interventional clinical registry is based on fully parametric database equipped by functional on-line system, centralized data management and electronic support of communication. Th e registry is aimed to follow diagnostics and therapy of HRPC. Optimized data set allows to assess the risk and prognostic factors as well as reference monitoring of therapeutic outcomes. Project contributes to the implementation of electronic patient’s documentation in this field. Detailed information and reporting is available in project portal http://ujo.registry.cz.
Key words:
epidemiology, hormone refractory prostate cancer, clinical registry, non-interventional monitoring.
Sources
1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–1520.
3. Ústav zdravotnických informací a statistiky ČR, Novotvary (Cancer Incidence in the Czech Republic); vydáváno každoročně, poslední vydání: rok 2005. ISBN 978-80-7280-723-9, dostupné z http://www.uzis.cz.
4. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005] [cit. 2008-8-26]. Dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.
5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARCPress 2004; http://www-dep.iarc.fr
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2009 Issue 2
Most read in this issue
- ATYPICAL TORSION OF THE TESTICULAR APPENDIX
- PROGNOSTIC VALUE OF p53, Ki-67 EXPRESSION IN THE UROTHELIAL CARCINOMA TISSUE AND URINARY BLADDER NONTUMOR MUCOSA
- DEVELOPMENT AND CLINICAL EVALUATION OF NEW DRUGS
- OUR EARLY EXPERIENCE WITH ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY - FIRST 153 CASES